153 abstracts found.



Results filter

Identification and triage of patient and carer needs: a clinician-rated tool for the clinic or surgery

Year:

Session type: ,

Miriam Johnson1

1University of Hull, Hull, UK


Novel intrapatient dose escalation phase I trial of two schedules of the combination of the PARP inhibitor olaparib and AKT inhibitor AZD5363 in BRCA1/2 and non-BRCA1/2 mutation patients with advanced cancers

Year:

Session type: ,

Timothy Yap1,2

1The Institute of Cancer Research, London, UK,2Royal Marsden Hospital, London, UK


Operationalising needs-based assessment

Year:

Session type: ,

David Currow1

1Flinders University, Adelaide, Australia


E-cigarettes and policy’

Year:

Session type:

Linda Bauld1

1Cancer Research UK, London, UK,2University of Stirling, Stirling, UK


Benefits and Harms of Preventive Therapy for Cancer

Year:

Session type: ,

Jack Cuzick1

1Queen Mary University of London, London, UK




Devising the ideal test for early diagnosis of cancer: lessons from the oesophagus

Year:

Session type: ,

Rebecca Fitzgerald1

1Univeristy of Cambridge, Cambridge, UK




How many cancers can we prevent through dietary modifications?

Year:

Session type: ,

Paolo Boffetta1

1Icahn School of Medicine at Mount Sinai, New York NY, USA


Hormone Therapy for Prostate Cancer

Year:

Session type: ,

Charles Sawyers1

1Memorial Sloan Kettering Cancer Center, New York, NY, USA


Circulating tumour cells and plasma DNA for non-invasive monitoring of cancers during their treatment

Year:

Session type: ,

Michael Speicher1

1Medical University of Graz, Graz, Austria




Working together in the Genomics Era – Lessons from the GTEOC study 

Year:

Session type: ,

Marc Tischkowitz1

1University of Cambridge, Cambridge, UK


The future role of primary care in cancer control – survivorship care

Year:

Session type: ,

Annette Berendsen1

1University of Groningen, Groningen, The Netherlands


microRNA mechanism and its involvement in DNA damage response pathway

Year:

Session type: ,

Martin Bushell1

1MRC Toxicology Unit, Leicester, UK


Selecting rational combinations for cancer and delivering early phase clinical trials in the UK.

Year:

Session type:

Hazel Jones1

1CRUK Centre for Drug Development, London, UK


Trends in electronic cigarette use in England

Year:

Session type: ,

Robert West1

1UCL, London, UK


Combinations Alliance from an Industry Perspective

Year:

Session type:

Susan Galbraith1

1AstraZeneca Oncology Innovative Medicines, Cambridge, UK


DEBIOC: A Combinations Alliance Study of AZD8931 in combination with Oxaliplatin and Capecitabine chemotherapy in patients with Oesophago-gastric adenocarcinoma

Year:

Session type: ,

Anne Thomas1

1University of Leicester, Leicester, UK




Physical activity, obesity and cancer

Year:

Session type: ,

Martin Wiseman1,2

1WCRF International, London, UK,2University of Southampton, Southampton, UK


Technological Developments in Radiotherapy

Year:

Session type: ,

Uwe Oelfke1

1Institute of Cancer Research, Sutton, Surrey, UK




Protective packaging for DNA: the role of the PBAF and INO80 chromatin remodelling complexes in maintaining genome stability

Year:

Session type: ,

Jessica Downs1

1Genome Damage and Stability Centre, Falmer, Brighton, UK


The genomic landscape of paediatric brain tumours – Recent advances

Year:

Session type:

David Jones1

1German Cancer Research Centre (DKFZ), Heidelberg, Germany




Role of the BRCA1:BARD1 Ubiquitin Ligase Activity in DNA repair.

Year:

Session type: ,

Jo Morris1

1University of Birmingham, West Midlands, UK




Phylogenetic analysis reveals divergent modes of clonal spread and intraperitoneal mixing in high grade serous ovarian cancer

Year:

Session type: ,

Sohrab Shah1,2

1BC Cancer Agency Research Centre, Vancouver, BC, Canada,2University of British Columbia, Vancouver, BC, Canada


What can observational studies tell us about early diagnosis of symptomatic cancer?

Year:

Session type: ,

Willie Hamilton1

1University of Exeter, Exeter, UK


Reducing prostate cancer progression and mortality: what you can do to reduce your risk

Year:

Session type:

Stacey Kenfield1,2

1University of California, San Francisco, San Francisco, CA, USA,2Harvard School of Public Health, Boston, MA, USA


Can we do RCTs of interventions to expedite the diagnosis of symptomatic cancer? And should we?

Year:

Session type: ,

Richard Neal1

1Bangor University, Bangor, UK


Big data and patient reported outcome measures (PROMs)

Year:

Session type: ,

Amy Abernethy1

1Flatiron Health, New York, NY, USA


Fc-mediated depletion of Tregs via ipilimumab-dependent ADCC in advanced melanoma patients

Year:

Session type:

Emanuela Romano1,2

1Dept. of Oncology, University Hospital of Lausanne, Lausanne, Switzerland,2Ludwig Cancer Research Center, Lausanne, Switzerland


Investigating the genomic landscape of brain tumours using metabolic imaging

Year:

Session type:

Kevin Brindle1

1University of Cambridge, Cambridge, UK


It takes a team: the importance of integration between primary care and cancer specialist care.

Year:

Session type: ,

Eva Grunfeld1

1Ontario Institute for Cancer Research, Toronto, Canada,2University of Toronto, Toronto, Canada


How do health economists value personalised medicine in oncology?

Year:

Session type: ,

Maarten IJzerman1

1University of Twente, Enschede, The Netherlands


Key role of AGO2 and the 8q24 amplicon in regulation of microRNA biogenesis in cancer

Year:

Session type: , ,

Laura Winchester1,Simon Wigfield1,Syed Haider1,Alan McIntyre1,Adrian Harris1,Francesca Buffa1

1University of Oxford, Oxford, UK


Mutations in the transcriptional repressor REST predispose to Wilms tumour

Year:

Session type: , ,

Shazia Mahamdallie1,Sandra Hanks1,Kristen Karlin2,3,Anna Zachariou1,Elizabeth Perdeaux1,Elise Ruark1,Chad Shaw3,Alexander Renwick3,Emma Ramsay1,Shawn Yost1,Anna Elliot1,The Wilms Tumor Susceptibility Collaboration (WTSC)1,Michael Capra4,Thomas McLean5,Anthony Renwick1,Sheila Seal1,Charles Stiller6,Neil Sebire7,Thomas Westbrook2,3,Nazneen Rahman1,8

1Division of Genetics & Epidemiology, Institute of Cancer Research, London, UK,2Verna & Marrs McLean Dept. of Biochemistry and Molecular Biology, Baylor College of Medicine, Houston, Texas, USA,3Dept of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas, USA,4Our Lady’s Children’s Hospital, Dublin, UK,5Wake Forest University School of Medicine, Winston-Salem, USA,6Public Health England, Oxford, UK,7Dept of Histopathology and Paediatric Laboratory Medicine, Great Ormond Street Hospital, London, UK,8Cancer Genetics Unit, Royal Marsden Hospital NHS Foundation Trust, London, UK


A randomised trial of interventions to increase uptake of cervical screening among 25 year old non-attenders; final results of the STRATEGIC Trial.

Year:

Session type: , ,

Henry Kitchener1,Matthew Gittins2,Carly Moseley1,Margaret Cruickshank3,Samantha Fletcher1,Jamie Oughton1,Rebecca Albrow1,Emma Crosbie1,Chris Roberts2

1Institute of Cancer Sciences, University of Manchester, Manchester, UK,2Institute of Population Health, University of Mancchester, Manchester, UK,3Department of Obstetrics and Gynaecology, University of Aberdeen, Aberdeen, UK


Can WBRT be omitted in NSCLC patients with brain metastases not suitable for stereotactic radiosurgery or surgical resection? Results from the UK Medical Research Council QUARTZ randomised clinical trial.

Year:

Session type: , ,

Paula Mulvenna1,Matthew Nankivell2,Rachael Barton3,Corinne Faivre-Finn4,Paula Wilson5,Barbara Moore6,Elaine McColl7,Iona Brisbane8,Dave Ardron2,Benjamin Sydes2,Cheryl Pugh2,Tanya Holt9,Neil Bayman4,Sally Morgan10,Caroline Lee11,Kathryn Waite12,Richard Stephens2,Max Parmar2,Ruth Langley2

1Northern Centre for Cancer Care, Newcastle upon Tyne, UK,2MRC Clinical Trials Unit at UCL, London, UK,3Castle Hill Hospital, East Yorkshire, UK,4The Christie, Manchester, UK,5Bristol Haematology & Oncology Centre, Bristol, UK,6University Hospital Llandough, South Glamorgan, UK,7Royal Victoria Infirmary, Newcastle upon Tyne, UK,8Beatson West of Scotland Cancer Centre, Glasgow, UK,9Mater Hospital, Brisbane, Queensland, Australia,10Nottingham University Hospitals, Nottingham, UK,11Weston Park Hospital, Sheffield, UK,12Queen Elizabeth Hospital, King’s Lynn, UK


5 year outcomes of a phase III randomised trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer [CRUK/06/016]: report from the CHHiP Trial Management Group

Year:

Session type: , ,

Emma Hall1,Isabel Syndikus2,Helen Mossop1,John Staffurth3,Christopher Scrase4,Miguel Panades5,Julian Money-Kyrle6,John Logue7,Vincent Khoo8,John Graham9,David Bloomfield10,Alison Birtle11,Jean Tremlett10,Olivia Naismith8,Helen Mayles2,Shama Hassan1,Clare Cruickshank1,Clare Griffin1,David Dearnaley1,8

1The Institute of Cancer Research, London, UK,2Clatterbridge Cancer Centre, Wirral, UK,3Velindre Cancer Centre, Cardiff, UK,4Ipswich Hospital, Ipswich, UK,5Lincoln County Hospital, Lincoln, UK,6Royal Surrey County Hospital, Guildford, UK,7Christie Hospital, Manchester, UK,8Royal Marsden NHS Trust, London, UK,9Musgrove Park Hospital, Taunton, UK,10Royal Sussex County Hospital, Brighton, UK,11Royal Preston Hospital, Preston, UK


Expanded analyses of NAPOLI-1: Phase 3 study of nal-IRI (MM-398), with or without 5-fluorouracil (5FU) and leucovorin (LV), versus 5-fluorouracil and leucovorin (5FU/LV), in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy

Year:

Session type: , ,

Richard Hubner1,Li-Tzong Chen2,3,Daniel D. Von Hoff4,5,Chung-Pin Li6,7,Andrea Wang-Gillam8,György Bodoky9,Andrew Dean10,Yan-Shen Shan2,3,Gayle Jameson5,11,Teresa Macarulla12,13,Kyung-Hun Lee14,Jean-Frédéric Blanc15,Chang-Fang Chiu16,Gilberto Schwartsmann17,Jens T. Siveke18,Fadi S. Braiteh19,Victor M. Moyo20,Bruce Belanger20,Eliel Bayever20,David Cunningham21

1The Christie NHS Foundation Trust, Manchester, UK,2National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan,3National Cheng Kung University Hospital, National Cheng Kung University, Tainan, Taiwan,4HonorHealth, Scottsdale, AZ, USA,5TGen, Scottsdale, AZ, USA,6Taipei Veterans General Hospital, Taipei, Taiwan,7National Yang-Ming University, Taipei, Taiwan,8Washington University in St. Louis, St. Louis, MO, USA,9St László Teaching Hospital, Budapest, Hungary,10St John of God Hospital, Subiaco, Western Australia, Australia,11Scottsdale Healthcare, Scottsdale, AZ, USA,12Vall d’Hebron University Hospital, Barcelona, Spain,13Vall d’Hebron Institute of Oncology, Barcelona, Spain,14Seoul National University Hospital, Seoul, Republic of Korea,15Hôpital Saint-André, Bordeaux, France,16China Medical University Hospital, Taichung, Taiwan,17Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil,18Klinikum rechts der Isar der TU München, Munich, Germany,19Comprehensive Cancer Centers of Nevada, Las Vegas, NV, USA


CheckMate 025: a randomized, open-label, phase III study of nivolumab versus everolimus in advanced renal cell carcinoma (RCC)

Year:

Session type: ,

Padmanee Sharma1,Bernard Escudier2,David F. McDermott3,Saby George4,Hans J. Hammers5,Sandhya Srinivas6,Scott S. Tykodi7,Jeffrey A. Sosman8,Giuseppe Procopio9,Elizabeth R. Plimack10,Daniel Castellano11,Howard Gurney12,Frede Donskov13,Petri Bono14,John Wagstaff15,Thomas C. Gauler16,Takeshi Ueda17,Li-An Xu18,Ian M. Waxman19,Robert J. Motzer20

1MD Anderson Cancer Center, University of Texas, Houston, TX, USA,2Institut Gustave Roussy, Villejuif, France,3Beth Israel Deaconess Medical Center, Dana-Farber/Harvard Cancer Center, Boston, MA, USA,4Roswell Park Cancer Institute, Buffalo, NY, USA,5Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA,6Stanford Cancer Institute, Stanford, CA, USA,7University of Washington and Fred Hutchinson Cancer Research Center, Seattle, WA, USA,8Vanderbilt University Medical Center, Nashville, TN, USA,9Fondazione Istituto Nazionale Tumori, Milan, Italy,10Fox Chase Cancer Center, Philadelphia, PA, USA,11Hospital Universitario 12 De Octubre, Madrid, Spain,12Westmead Hospital, New South Wales, Australia,13Aarhus University Hospital, Aarhus, Denmark,14Comprehensive Cancer Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland,15South West Wales Cancer Institute and Swansea University College of Medicine, Swansea, UK,16University Hospital Essen of University of Duisburg-Essen, Essen, Germany,17Chiba Cancer Center, Chiba, Japan,18Bristol-Myers Squibb, Hopewell, NJ, USA,19Bristol-Myers Squibb, Lawrenceville, NJ, USA


Physical activity levels and barriers to exercise referral among patients with cancer

Year:

Session type: , ,

Dorothy Yang1,Omar Hausien1,Mohammed Aqeel1,Alexios Klonis1,Jo Foster2,Derek Renshaw3,Robert Thomas4

1University of Cambridge School of Clinical Medicine, Cambridge, UK,2Macmillan Cancer Support, London, UK,3Coventry University, Coventry, UK,4Addenbrooke’s Cambridge University Hospitals NHS Trust, Cambridge, UK,5Bedford Hospital NHS Trust, Bedford, UK


Effect of pre-diagnostic NSAID use on ovarian cancer survival

Year:

Session type: , ,

Chris Brown1,Thomas Ian Barron2,Kathleen Bennett2,Linda Sharp1,3

1National Cancer Registry Ireland, Cork, Ireland,2Trinity College Dublin, Dublin, Ireland,3Newcastle University, Newcastle, UK


E-cadherin deficiency a novel determinant of ROS1 inhibitor sensitivity

Year:

Session type: , ,

Ilirjana Bajrami1,Stephen Pettitt1,Rachel Brough1,Helen Pemberton1,Jessica Frankum1,James Campbell1,Alan Ashworth2,Christopher Lord1

1ICR, LONDON, UK,2UCSF, SAN FRANCISCO, USA


MAMMO-50: The results of the pre-planned internal 2 year feasibility study for Mammographic surveillance in early breast cancer patients over 50 years of age at diagnosis

Year:

Session type: , ,

J.A. Dunn1,P.K Donnelly2,A. Marshall1,M. Wilcox3,E. Watson4,M. Ramirez1,S. Hartup5,P. Mistry1,A. J. Maxwell6,A. J Evans7

1Warwick Clinical Trials Unit, Coventry, UK,2South Devon Healthcare NHS Foundation Trust, Torquay, UK,3Independent Cancer Patient Voices, London, UK,4Department of Clinical Healthcare, Oxford Brookes University, Oxford, UK,5St James’s University Hospital, Leeds, UK,6University Hospital of South Manchester NHS Foundation Trust, Manchester, UK,7Ninewells Medical School, Dundee, UK


Targeted next-generation sequencing: cell-free DNA profiles mirror the heterogeneity of single CTCs

Year:

Session type: , ,

David Guttery1,Karen Page1,Allison Hills2,Laura Woodley2,Genny Buson3,Raimo Tanzi3,Henrik Tommerup3,Justin Stebbing2,Charles Coombes2,Jacqueline Shaw1

1Department of Cancer Studies and Cancer Research UK Leicester Centre, Leicester, UK,2Imperial College, Department of Surgery and Cancer, Charing Cross Hospital, London, UK,3Silicon Biosystems, Bologna, Italy


The splicing inhibitor Spliceostatin A downmodulates Mcl-1 expression and induces a potent apoptotic response in Chronic Lymphocytic Leukaemia cells

Year:

Session type: , ,

Marta Larrayoz1,Stuart J Blakemore1,Rachel Dobson1,Matthew JJ Rose-Zerilli1,Renata Walewska2,Matthew D Blunt1,Minoru Yoshida3,David Oscier2,Mark S Cragg1,Andrew J Steele1,Jonathan C Strefford1

1Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Southampton, UK,2Department of Haematology, Royal Bournemouth Hospital, Bournemouth, UK,3Cehmical Genomics Group, RIKEN Center for Sustainable Resource Science, Wako, Japan


CTEN (C-terminal Tensin-like) regulates head and neck cancer invasion and survival

Year:

Session type: , ,

Jason Fleming1,Veronika Jenei1,Karwan Moutasim1,Matthew Ward1,Emma King1,4,Sassan Hafizi2,Dae Kim3,Jeremy Blaydes1,Gareth Thomas1

1University of Southampton, Southampton, UK,2University of Portsmouth, Portsmouth, UK,3St. George’s University Hospitals, London, UK,4Poole Hospital NHS Foundation Trust, Poole, UK


Signatures of ionising radiation in second malignancies

Year:

Session type: , ,

Sam Behjati1,Gunes Gundem1,David Wedge1,Patrick Tarpey1,Nicole Roberts1,Andrea Richardson2,Ultan McDermott1,Steven Bova3,Adrienne Flanagan4,Michael Stratton1,Peter Campbell1

1Wellcome Trust Sanger Institute, Hinxton, UK,2Harvard Medical School, Boston, UK,3University of Tampere and Fimlab Laboratories, Tampere, Finland,4University College London, London, UK


A National Platform for Molecular Diagnostics: Results from Phase I of the Cancer Research UK Stratified Medicine Programme

Year:

Session type: , ,

Colin R Lindsay1,Emily Shaw1,James D Brenton2,Rachel Butler3,Jim Davies4,David Gonzalez de Castro5,Mike Griffiths6,Andrew Hanby7,Steve Harris4,David J Harrison8,Stephen R D Johnston9,Malcolm Mason10,Dion Morton11,Andrew G Nicholson12,Karin Oien13,Doris Rassl14,Jane Rogan15,Ian Walker1,Peter W M Johnson1

1Cancer Research UK, London, UK,2Cancer Research UK Cambridge Institute, Cambridge, UK,3Institute of Medical Genetics, Cardiff, UK,4University of Oxford, Oxford, UK,5The Centre for Molecular Pathology, Surrey, UK,6West Midlands Regional Genetics Laboratory, Birmingham, UK,7Leeds Institute of Cancer and Pathology, Leeds, UK,8University of St. Andrews, St. Andrews, UK,9The Royal Marsden NHS Foundation Trust, London, UK,10Cardiff University, Cardiff, UK,11The Queen Elizabeth Hospital, Birmingham, UK,12Royal Brompton and Harefield Hospitals NHS Foundation Trust, London, UK,13NHS Greater Glasgow and Clyde, Glasgow, UK,14Papworth Hospital NHS Foundation Trust, Cambridge, UK,15Manchester Cancer Research Centre, Manchester, UK


Real-Time Diagnosis of Ovarian Cancer with the Surgical Intelligent Knife (iKnife)

Year:

Session type: , ,

David Phelps1,Julia Balog1,2,Mona El-Bahrawy1,Abigail Speller1,Zoltan Takats1,Robert Brown1,Sadaf Ghaem-Maghami1

1Imperial College, London, UK,2Waters Corporation, Budapest, Hungary


Public understanding of the purpose of cancer screening: a population-based survey

Year:

Session type: , ,

Jo Waller1,Yasemin Hirst1,Jane Wardle1,Christian von Wagner1

1UCL, London, UK


Variations in GPs’ Decisions to Investigate Suspected Lung Cancer: A Factorial Experiment Using Multimedia Vignettes

Year:

Session type: , ,

Jessica Sheringham1,Rachel Sequeira1,Jonathan Myles2,Willie Hamilton3,Joe McDonnell4,Judith Offman2,Stephen Duffy2,Rosalind Raine0

1UCL, London, UK,2QMUL, London, UK,3University of Exeter, Exeter, UK,4London Borough of Waltham Forest, London, UK


Children’s Cancer and Leukaemia Group (CCLG) McElwain Award winner – Adamantinomatous craniopharyngioma contains senescent cells with tumour-inducing potential

Year:

Session type: , ,

Mario Jose Gonzalez-Meljem1,Gabriela Carreno1,John Apps1,Scott Haston1,Christina Stache1,Tomas Stanley Jacques2,5,Colin Goding3,Jesus Gil4,Cynthia Lilian Andoniadou1,Juan Pedro Martinez-Barbera1

1University College London, London, UK,2University of Oxford, Oxford, UK,3Imperial College London, London, UK,4King’s College London, London, UK,5Great Ormond Street Hospital, London, UK